A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition with Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients with Metastatic Colorectal Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2016
At a glance
- Drugs Erlotinib (Primary) ; Panitumumab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 16 Jun 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 16 Jun 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology